These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-003075-37 CHOEP-14 + rituximab with CNS prophylaxis in patients less than 65 years with Diffuse Large B-Cell Lymphoma/Follicular Lymphoma grade III, stage II-IV with risk factors (age adjusted IPI) ≥ 2. A phase... not-yet-due
Ongoing 2006-000389-35 A Nordic phase II study of peripheral T-cell lymphomas based on dose-intensive induction and high-dose consolidation with autologous stem cell rescue not-yet-due
Reported results 2006-004772-12 Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by ma... 2022-07-13 due-trials
Listed as ongoing, but also has a completion date 2006-006130-17 ACT-1 (younger patients) A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versu... 2016-12-31 bad-data
Exempt, with results 2008-007246-60 Lenalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma 2017-06-30 not-yet-due
Listed as ongoing, but also has a completion date 2010-023125-38 Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk (aaIPI≥2) Diffuse Large B-Cell Lymphoma (NLG-LBC05) 2020-05-25 bad-data
Ongoing 2011-001557-85 NLG-MCL5 (MARiT) Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 years A Nordic Lymphoma Group and British Lymphoma Group Phase-II Trial not-yet-due
Reported results 2013-005541-36 A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma. 2019-12-31 due-trials
Reported results 2016-001058-16 A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma. 2021-09-30 due-trials
Ongoing 2017-001060-38 Venetoclax, lenalidomide and rituximab in patients with relapsed/refractory mantle cell lymphoma. not-yet-due
Ongoing 2018-001850-80 Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma not-yet-due